PGPeter Gocke

Peter Gocke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter Gocke has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • R.-D. Müller

    Department of Diagnostic Radiology, University of Essen, Essen, Germany

    8 shared publications
  • B. Buddenbrock

    Central Institute of Diagnostic Radiology, University Hospital of Essen, Hufelandstrasse 55, D-45 122 Essen, Germany DE

    6 shared publications
  • H. Hirche

    Institute of Medical Informatics, Biometry and Epidemiology, University of Essen, Hufelandstrasse 55, D-45 122 Essen, Germany DE

    6 shared publications
  • C. Gocke

    Department of Diagnostic Radiology, University of Essen, Essen, Germany

    5 shared publications
  • R. Wiebringhaus

    Central Institute of Diagnostic Radiology, University Hospital of Essen, Hufelandstrasse 55, D-45 122 Essen, Germany DE

    5 shared publications
  • V. John

    Central Institute of Diagnostic Radiology, University Hospital of Essen, Hufelandstrasse 55, D-45 122 Essen, Germany DE

    5 shared publications

Latest Publications

  • Open Access

    The Coordination on Mobile Pandemic Apps Best Practice and Solution Sharing (COMPASS) Framework: Holistic Approach to Pandemic mHealth Apps

    by Christian Elsner, Michael Winter, Peter Gocke, Rüdiger Pryss, Dagmar Krefting

    The COVID-19 pandemic has highlighted the crucial role of smartphone apps in public health, but it has also revealed challenges in terms of user acceptance and trust, as well as the secure integration of medical data. To overcome these, the COMPASS initiative (Coordination on Mobile Pandemic Apps Best Practice and Solution Sharing)—part of the German Network University Medicine (NUM) program—developed a structured framework for the coordinated development and delivery of pandemic apps, with a focus on usability, accessibility, security, and scalability. By incorporating expertise from 9 university hospitals and external partners, COMPASS provided a modular approach to pandemic app development that balances technology, regulation, and public acceptance. The framework includes governance, best practices, compliance, research compatibility, interoperability, and a scalable technology platform. In addition, standardized app components and templates were created to support an effective pandemic response. Real-world validation was provided by study-specific apps such as the Mainz Gutenberg Study COVID-19 app (University Medical Center Mainz) and the SentiSurv app (University Medical Center Mainz), which generated nearly 1 million data points from over 25,000 participants. COMPASS successfully developed study-specific apps, improved core functionalities, and contributed to larger digital health projects such as the InnovationHub CAEHR. Beyond its immediate applications, COMPASS serves as a scalable blueprint for future mobile health solutions, with a focus on data protection, user trust, and open-source collaboration. By integrating important technological, ethical, and user-oriented considerations, it sets a new standard for digital health innovation and ensures sustainable and widely accepted pandemic preparedness.

  • Open Access

    ePA4all—Exploring facilitators and barriers to the adoption of the electronic health record in Germany: A study protocol for a mixed-methods analysis

    by Susann May, Felix Muehlensiepen, Gina Barzen, Frances Seifert, Manuela Marquardt, Charly Bunar, Lena Dimde, Dennis Kipping, Peter Gocke, Philipp Stachwitz, et al.

    Background: This manuscript presents the study protocol for a planned mixed-methods study on the transition to an opt-out approach for the electronic health record (elektronische Patientenakte, ePA) in Germany in 2025. This change represents a paradigm shift in the healthcare system and aims to promote broad adoption. While the ePA has the potential to improve cross-sectoral care and patient empowerment, structural and individual barriers may hinder successful implementation. Understanding these factors is crucial to developing strategies for effective integration and long-term utilization of the ePA. Objective: This study aims to systematically investigate the barriers and facilitators influencing the adoption and use of the ePA among various user groups, including both patients and healthcare providers, in Germany. It seeks to identify sociodemographic and contextual factors affecting acceptance and usage while also exploring the ePAs potential to optimize healthcare processes, patient satisfaction, and empowerment. Methods: This mixed-methods exploratory study employs the Consolidated Framework for Implementation Research to examine the structural, organizational, and individual determinants of ePA implementation. Data will be collected in four modules: (1) patient interviews and surveys with ePA users and nonusers, (2) analysis of aggregated usage data from all ePAs in Germany, (3) interviews and surveys with stakeholders in outpatient and emergency care, and (4) focus groups for validation and synthesis of findings. Quantitative analyses include descriptive statistics and regression models, whereas qualitative data will be analyzed using structured content analysis. Discussion: This study is expected to provide a comprehensive understanding of the factors that affect ePA adoption and use in Germany. Insights from different perspectives will inform targeted strategies to overcome barriers, strengthen health literacy, and enhance system usability. These insights will contribute to recommendations for optimizing the implementation of the ePA in Germany and promoting the digital transformation of the German healthcare system.


  • Reformbedarf: Quo vadis, Gesundheitswesen?

    by Peter Gocke

    Sowohl die Pandemie-Folgen als auch die durch den Krieg in der Ukraine ausgelösten wirtschaftlichen Verwerfungen stellen eine erhebliche Bedrohung für unser Gesundheitswesen dar: Erstmals zeichnen sich Klinik-Insolvenzen in einem bisher nicht beobachteteten Ausmaß ab und bringen auch größere Einheiten in Schieflage. Article published online: 06 April 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Digitale Transformation: Das Gesundheitswesen der Zukunft wird anders

    by Peter Gocke

    Wenn diese Ausgabe der kma erscheint, werden wir immer noch mit den Auswirkungen der Pandemie kämpfen – bald zwei Jahre nach dem ersten Nachweis einer Sars-CoV-2-Infektion in Deutschland. In dieser angespannten Situation auch noch die digitale Transformation voranzutreiben, ist nicht einfach. Zwar steht jetzt mit dem Krankenhaus-Zukunftsgesetz (KHZG) Geld zumindest für Krankenhäuser zur Verfügung, und verschiedenste Gesetze forcieren den Ausbau der Telematikinfrastruktur zu einem hoffentlich bald funktionsfähigen, national vernetzten Gesundheitssystem – aber die in den letzten beiden Jahren erzielten Fortschritte bleiben überschaubar: Immer noch gibt es technische Schwierigkeiten bei der Anbindung über die vorgeschriebenen Konnektoren, und Dienste und Services wie die elektronische Patientenakte kommen nur in homöopathischen Dosen bei den Patienten an. Andere hilfreiche Services wie die elektronische Arbeitsunfähigkeitsbescheinigung oder das E-Rezept starten ebenso zögerlich mit aus guten Gründen erforderlichen verlängerten Übergangsfristen, in denen die Papierprozesse weitergeführt werden können. Publication Date: 03 January 2022 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • EHDS: Europäischer Datenpool für innovative Medizin

    by Peter Gocke, Antonia Rollwage

    Die Schaffung eines gemeinsamen europäischen Gesundheitsdatenraumes (EDHS) steht auf der Prioritätenliste der Europäischen Kommission ganz oben. Bis 2025 soll der European Health Data Space einen DSGVO-konformen Zugang zu Gesundheitsdaten ermöglichen und auf Basis einheitlicher Regeln neue digitale Gesundheitsdienste fördern. Publication Date: 28 May 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Digitalisierung des Gesundheitswesens: Den Blick nach vorne richten

    by Peter Gocke

    Noch stecken wir mitten in der Pandemie und sind damit beschäftigt, die nächsten Wochen und Monate durchzustehen. Publication Date: 10 March 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • The Incidence of Acute Kidney Injury and Associated Hospital Mortality

    by Dmytro Khadzhynov, Danilo Schmidt, Juliane Hardt, Geraldine Rauch, Peter Gocke, Kai-Uwe Eckardt, Kai M. Schmidt-Ott

    Studies from multiple countries have shown that acute kidney injury (AKI) in hospitalized patients is associated with mortality and morbidity. There are no reliable data at present on the incidence and mortality of AKI episodes among hospitalized patients in Germany. The utility of administrative codings of AKI for the identification of AKI episodes is also unclear. In an exploratory approach, we retrospectively analyzed all episodes of AKI over a period of 3.5 years (2014-2017) on the basis of routinely obtained serum creatinine measurements in 103 161 patients whose creatinine had been measured at least twice and who had been in the hospital for at least two days. We used the "Kidney Disease: Improving Global Outcomes" (KDIGO) criteria for AKI. In parallel, we assessed the administrative coding of discharge diagnoses of the same patients with codes from the International Classification of Diseases (ICD-10-GM). Among 185 760 hospitalizations, stage 1 AKI occurred in 25 417 cases (13.7%), stage 2 in 8503 cases (4.6%), and stage 3 in 5881 cases (3.1%). AKI cases were associated with length of hospital stay, renal morbidity, and overall mortality, and this association was stage-dependent. The in-hospital mortality was 5.1% for patients with stage 1 AKI, 13.7% for patients with stage 2 AKI, and 24.8% for patients with stage 3 AKI. An administrative coding for acute kidney injury (N17) was present in only 28.8% (11 481) of the AKI cases that were identified by creatinine criteria. Like the AKI cases overall, those that were identified by creatinine criteria but were not coded as AKI had significantly higher mortality, and this association was stage-dependent. AKI episodes are common among hospitalized patients and are associated with considerable morbidity and mortality, yet they are inadequately documented and probably often escape the attention of the treating physicians.


  • Open Access

    Web-Based Patient-Reported Outcomes Using the International Consortium for Health Outcome Measurement Dataset in a Major German University Hospital: Observational Study

    by Maria M Karsten, Dorothee Speiser, Claudia Hartmann, Nele Zeuschner, Kai Lippold, Verena Kiver, Peter Gocke, Valerie Kirchberger, Jens-Uwe Blohmer

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Collecting patient reported outcome (PRO) data in a systematic way enables an objective evaluation of treatment and its related outcomes. By using the disease specific questionnaires developed by the International Consortium of Health Outcome Measurement (ICHOM) this allows for comparison between physicians, hospitals and even different countries. Objective: The aim of this pilot project was to establish a digital system to measure patient reported outcomes for new breast cancer patients who attended the Charité Breast cancer clinic. This approach should serve as a blueprint to further expand the PRO measurement to other disease entities and departments. Methods: In November 2016 we implemented a web-based system to collect PRO data at the breast center at Charité University hospital using the ICHOM data set. All new patients at the breast center were enrolled and were answering a predefined set of questions using a tablet computer. Once they start their treatment at Charité automated emails were sent to the patient at predefined treatment points. Those emails contained a web-based link through which they could access and answer questionnaires. Results: By now 541 patients have been enrolled and 2470 questionnaires initiated. 9.44% of the patients were under the age of 40, 49.7% between 40 and 60, 39.6% between 60-80 and 1.3% over the age of 80. The average return rate of questionnaires was 67%. When asked about preference regarding paper versus online questionnaires 6% of the patients between 50 to 60 , 6% between 60-70 and 13 % over 70 would prefer paper versions. Conclusions: Measuring PRO in breast cancer patients in an automated electronic version is possible across all age ranges while simultaneously achieving a high return rate.


  • Open Access

    Web-Based Patient-Reported Outcomes Using the International Consortium for Health Outcome Measurement Dataset in a Major German University Hospital: Observational Study (Preprint)

    by Maria M Karsten, Dorothee Speiser, Claudia Hartmann, Nele Zeuschner, Kai Lippold, Verena Kiver, Peter Gocke, Valerie Kirchberger, Jens-Uwe Blohmer

    BACKGROUND Collecting patient-reported outcome (PRO) data systematically enables objective evaluation of treatment and its related outcomes. Using disease-specific questionnaires developed by the International Consortium for Health Outcome Measurement (ICHOM) allows for comparison between physicians, hospitals, and even different countries. OBJECTIVE This pilot project aimed to establish a digital system to measure PROs for new patients with breast cancer who attended the Charité Breast Center This approach should serve as a blueprint to further expand the PRO measurement to other disease entities and departments. METHODS In November 2016, we implemented a Web-based system to collect PRO data at Charité Breast Center using the ICHOM dataset. All new patients at the Breast Center were enrolled and answered a predefined set of questions using a tablet computer. Once they started their treatment at Charité, automated emails were sent to the patients at predefined treatment points. Those emails contained a Web-based link through which they could access and answer questionnaires. RESULTS By now, 541 patients have been enrolled and 2470 questionnaires initiated. Overall, 9.4% (51/541) of the patients were under the age of 40 years, 49.7% (269/541) between 40 and 60 years, 39.6% (214/541) between 60 and 80 years, and 1.3% (7/541) over the age of 80 years. The average return rate of questionnaires was 67.0%. When asked about the preference regarding paper versus Web-based questionnaires, 6.0% (8/134) of the patients between 50 and 60 years, 6.0% (9/150) between 60 and 70 years, and 12.7% (9/71) over the age of 70 years preferred paper versions. CONCLUSIONS Measuring PRO in patients with breast cancer in an automated electronic version is possible across all age ranges while simultaneously achieving a high return rate.


  • Impact of Estrogen Replacement Therapy in a Male with Congenital Aromatase Deficiency Caused by a Novel Mutation in the CYP19 Gene

    by Burkhard Lorenz Herrmann, Bernhard Saller, Onno Eilard Janssen, Peter Gocke, Andreas Bockisch, Herbert Sperling, Klaus Mann, Martina Broecker

    Recent reports of the impact of estrogen receptor alpha and aromatase deficiency have shed new light on the importance of estrogen for bone formation in man. We describe a novel mutation of the CYP19 gene in a 27-yr-old homozygous male of consanguinous parents. A C to A substitution in intron V, at position -3 of the splicing acceptor site before exon VI of the CYP19 gene, is the likely cause of loss of aromatase activity. The mRNA of the patient leads to a frameshift and a premature stop codon 8 nucleotides downstream the end of exon V. Both parents were shown to be heterozygous for the same mutation. Apart from genua valga, kyphoscoliosis, and pectus carniatus, the physical examination was normal including secondary male characteristics with normal testicular size. To substitute for the deficiency, the patient was treated with 50 micro g transdermal estradiol twice weekly for 3 months, followed by 25 micro g twice weekly. After 6 months estrogen levels (1.150). Osteocalcin as a bone formation parameter increased from 13 to 52 micro g/l (normal range, 24-70) and aminoterminal collagen type I telopeptide as a bone resorption parameter increased from 62.9 to 92.4 nmol/mmol creatinine (normal range, 5-54). Semen analysis revealed oligoazoospermia (17.4 million/ml; normal >20) at baseline. After 3 months of treatment, the sperm count increased (23.1 million/ml) and decreased rapidly (1.1 million/ml) during the following 3 months. The sperm motility was reduced at baseline and decreased further during treatment. Area under the curve of insulin, C-peptide, and blood glucose levels during oral glucose tolerance test decreased after 6 months (insulin: 277 vs. 139 micro U/ml.h; C-peptide 52 vs. 15 ng/m.h; area under the curve glucose: 17316 vs. 12780 mg/d.min). Triglycerides (268 vs. 261 mmol/liter) and total cholesterol levels (176 vs. 198 mmol/liter) did not change significantly, but the low-density lipoprotein/high-density lipoprotein ratio decreased from 5.37 to 3.56 and lipoprotein (a) increased from 19.9 to 60.0 mg/dl (normal range, <30). In this rare incidence of estrogen deficiency, estrogen replacement demonstrated its importance for bone mineralization and maturation and glucose metabolism in a male carrying a novel mutation in the CYP19 gene.